SCR7

NHEJ pathway inhibitor; inhibits DNA ligase IV

More Views

From: 97 USD

Options

* Required Fields

Catalog # (Select a product)
NHEJ pathway inhibitor; inhibits DNA ligase IV
From: 97 USD

Overview

SCR7 is an inhibitor of DNA ligase IV, which is responsible for the repair of DNA double-strand
breaks via the non-homologous end joining (NHEJ) repair pathway (Srivastava et al.). Due to its reported success in impeding cancer cell growth and potential impact on future cancer therapeutics, SCR7 has been closely studied in many recent publications (Hosoya & Miyagawa; John et al.).


GENOME EDITING
·Inhibits NHEJ-dependent DNA repair; this inhibition is reported to enhance precise homology-directed repair (HDR)-dependent CRISPR-Cas9 genome editing (Chu et al.; Maruyama et al.; Pinder et al.). However, these effects are cell type-specific and context-dependent (Song et al.; Xie et al.; Yang et al.; Zhang et al.).

CANCER RESEARCH
·Activates apoptosis of cancer cells by inhibiting DNA ligase IV to increase the efficacy of DNA double-strand break-inducing therapy (chemo- or radio-therapy) (Srivastava et al.).
Alternative Names:
Not applicable
CAS Number:
1533426-72-0
Chemical Formula:
C₁₈H₁₄N₄OS
Molecular Weight:
334.4 g/mol
Purity:
≥ 95%

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(5)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area Workflow Stages for
Workflow Stages
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.